AR may increase hospitalisation in asthma 8
- Asthma patients with coexisting AR are 1.5 times more likely to have an asthma-related hospitalisation than those without 8
- They are also more likely to have emergency room visits (3.6% vs 1.7%, p=0.029) 8
Combined treatment may improve QoL 7
- Combining treatment strategies in patients with AR and asthma may reduce medical treatment costs and improve symptom control and QoL 7
AR: allergic rhinitis; QoL: quality of life
References
- Seidman M, Gurgel RK, Lin SY, et al. Clinical Practice Guideline: Allergic Rhinitis. Otolaryngol Head Neck Surg 2015;152(18):S1–S43.
- Demoly P, Bousquet J. The relation between asthma and allergic rhinitis. Lancet 2006;368:711–713.
- Brozek J, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol 2017;140(4):950–958.
- Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002;109:419–425.
- Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008;63(Suppl. 86):8–160.
- Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002;109(4):636–642.
- Bourdin A, Gras D, Vachier I, Chanez P. Upper airway x 1: allergic rhinitis and asthma: united disease through epithelial cells. Thorax 2009;64:999–1004.
- Bousquet J, Gaugris S, Kocevar VS, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. Clin Exp Allergy 2005;35(6):723–727.
Avamys is a registered trademark of the GlaxoSmithKline group of companies